Treatment with Zynlonta (loncastuximab tesirine) is helping to push high-risk follicular lymphoma and marginal zone lymphoma into complete remission for a majority of the…
News
PANCREATIC CANCER
Bizengri gets FDA approval for advanced pancreatic cancer
Bizengri (zenocutuzumab-zbco) is now approved in the U.S. as the first treatment for advanced pancreatic cancer and non-small cell lung cancer (NSCLC) harboring an…
Treovir has launched a Phase 2 clinical trial to assess the safety and efficacy of G207, an experimental virus-based therapy, for pediatric recurrent high-grade…
GYNECOLOGICAL CANCER
Keytruda added to chemo slows ovarian cancer growth: Phase 3 trial
Adding Keytruda (pembrolizumab) to chemotherapy, followed by maintenance treatment with Lynparza (olaparib), delayed cancer progression more effectively than chemotherapy alone in women with…
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier this year as a second-line treatment for people with multiple myeloma — was shown to delay…
In people with acute myeloid leukemia (AML), changes in the gene profile of blood-forming stem cells, leading to a more youthful blood cell profile, could…
PANCREATIC CANCER
PRKAA1 protein seen among pancreatic cancer biomarkers: Study
A protein called PRKAA1 could be among potential pancreatic cancer biomarkers and a possible treatment target, a study found. Levels of the protein were…
Researchers have uncovered genetic changes that may explain why certain brain tumors, known as gliomas, that are associated with IDHÂ gene mutations start off as…
GYNECOLOGICAL CANCER
Vulvar cancer possibly tied to bacteria not known in such cancers
The first recorded case of vulvar cancer that occurred alongside an infection with the Fusobacterium necrophorum bacteria was described in a recent case report…
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
Recent Posts
- Study of gynecological cancer therapy moving fast in summer slowdown
- The caregiver’s invisible ledger tracks what no one else sees
- Study shows protein marker helps predict aggressive myeloma
- New combination therapy cuts risk of death in hard-to-treat myeloma
- Early AML trial finds experimental therapy was generally well tolerated
